Objectives: we investigated the therapeutic effect of angioplasty with local drug delivery (LDD) of the wall-accumulating NO-donor molsidomine (M) in the superficial femoral arteries (SFA) of atherosclerotic swine. Materials and methods: atherosclerotic Pietrin swines (n=14) underwent PTA-LDD-M (4 mg/2 ml) vs contralateral PTA-LDD-Placebo in the SFA using a channelled balloon angioplasty catheter. Invasive and colour Doppler energy (CDE) assessments of haemodynamics and wall mechanics were performed at 24 h (n=4) and 5 months (n=10). Immunohistolabelling of cell proliferation and histomorphometry were serially performed in perfusion fixed SFA samples. Results: at 24 h, PCNA-positive nuclei revealed 33±14 and 12±3 proliferating cells/mm 2 at placebo and molsidomine PTA-LDD sites, respectively (p<0.001). At 5 months, PTA-LDD-M vessels, compared with PTA-LDD-P, had increased compliance (66±9 vs 11±4 ml/mmHg) and lowered impedance (0.11±0.05 vs 0.45±0.14 mmHg/ml min −1 ) (p<0.05). CDE revealed low, middle and high velocity peaks at 7.5, 20 and 35, and 8, 15 and 22 cm s −1 in systolic and diastolic flows, respectively; and PTA-LDD-M prevented emergence of restenosis-associated increases in low blood velocities (p<0.01). PTA-LDD-M inhibited restenotic intimal thickening and medial thinning which decreased mean lumenal diameter in placebo-treated (2.6±0.3) as compared to molsidomine-treated (3.4±0.3 mm) vessels (p<0.05). Conclusions: in the atherosclerotic porcine SFA model, PTA-LDD with molsidomine consistently improved haemodynamic wall mechanics, lowered cell proliferation and prevented late lumen loss observed with PTA-LDD with placebo.
Introduction
inhibit thrombosis, 12, 13 inhibit extra-cellular matrix deposition 7, [14] [15] [16] and promote the maintenance of nor-Following angioplasty in the superficial femoral artery mal, vascular smooth muscle function, and inhibit (SFA), only 50% of patients show long-term sympinflammation. 11,14-18 tomatic improvement. 1-3 Specifically, the clinical out-
The sydnonimines, especially molsidomine, liberate come appears to be dependent upon (i) haemodynamic NO leading to development of tolerance. 19, 20 They have success and restoration of wall mechanics post-interno specific intramural binding properties, 11 but when vention, (ii) reactive and adaptive remodelling procoupled with the channelled balloon angioplasty cathcesses, 2,4,5 and (iii) thrombo-embolic complications. 2,4 eter, there appears [21] [22] [23] [24] capable of efficient, transmural Atherosclerotic swine provide a good model of the drug delivery. Furthermore, this agent has a unique human situation. [6] [7] [8] [9] Local drug delivery (LDD) is a property of accumulating in significant amounts logical approach to post-angioplasty restenosis and within the heart muscle and arterial walls. 25 In a porocclusion in the SFA. 8-10 Specifically, nitric oxide (NO)cine model we have previously reported that these donors 11 affect vascular tone and wall dynamics, 11, 12 compounds have a beneficial impact on restenosis through effects on NO and vascular smooth muscle cells. 7, [26] [27] [28] [29] [30] sydnonimines at the time of PTA, 31,32 continued or not by oral administration of molsidomine, have yielded promising results with the conclusions that both chemical nature of the NO-donor and drug delivery device must be optimised in order to yield the expected anti-restenotic effect. 26, 32, 33 The present study therefrom investigate the haemodynamic and morphologic consequences of molsidomine delivery with the channelled angioplasty balloon in the SFA in the atherosclerotic swines.
Materials and Methods

Experimental protocol
The animals were handled in accordance with the Guide for the Care and Use of Laboratory Animals (National Research Council, Natl Acad Press, Washington, DC, U.S. A., 1996) . For 6 months, 14 male Pietrin pigs (40.9±4.2 kg at 6 months of age; Blossin SA, Aubagne, France) were fed the Marseille atherogenic diet which accelerates development of atherosclerosis. 6, 30, 31 At 6 months, angioplasty with local drug delivery (AP-LDD) was performed with molsidomine and placebo in bilateral superficial femoral arteries (SFA); and the animals were placed back on control diet. 30, 31 Twenty-four hours (n=4) and 5 months (n= 10) after AP-LDD, animals were submitted to angiographic, haemodynamic, vascular wall rheologic were pressure fixed at physiologic condition and 14) . Microphotograph illustrates that atherosclerotic lesions in the sampled for histomorphological assessment. 29 SFA contained a fibrous cap (FibC), a lipidic core (LpC) with focal necrosis (nec) and media intimalisation (MedInt) with elastic laminae disruption (red arrow) and reorientation and migration of smooth muscle cells (black arrow).
Radiologic procedures and angioplasties saphenous artery (ISA) branch and the popliteal-posterior tibial arteries (PopA-postTA) bifurcation (Fig. All procedures were performed on anaesthetised pigs 28, 29 in dorsal position with the lower legs folded 1). The pre-procedure lumenal diameter by using the dimensional characteristics of the balloon. A 3 min down thereby defining the radiologic posture. A digitised subtraction angiographic Stenoscop system (Gen-inflation time at 10 atm was performed using a mixture of saline and contrast medium (50:50, v/v) during eral Electric Medical System, Minneapolis, U.S.A.) was used for radiologic procedures with access through which molsidomine delivery was conducted by a 2 min perfusion time at 1 ml/min, at 6 atm (60 and 10 ml, surgically isolated, right carotid artery (7F vascular sheath, Cordis/J&J, Miami, FL, U.S.A.). No heparin Leveen Inflators, BSC-MediTech). Molsidomine (4 mg/ 2 ml) and control saline solution (2 ml isotonic sodium was used. Routine angiograms were obtained from a NightHawk angiographic catheter (5F, 100 cm, BSC-chloride solution containing dextran 60 -6%, p/v and glucose, 10%, p/v) in ampules were a kind gift from MediTech, Watertown, MA, U.S.A.) advanced over a glidex-coated hydrophilic 0.035 in guidewire (BSC-Dr Grewe (Hoechst, Taunus, Germany). The lumen diameter of the SFAs was 5.4±0.3 mm (n=14), with a MediTech). The channelled balloon angioplasty catheter (BSC-CB, 6×40 mm; Boston Scientific Corp, Na-1.10-1.15:1 balloon/artery diameter ratio. The sequence for local drug delivery involved AP-LDD tick, MA, U.S.A.) was advanced in between the internal using control saline in one SFA, randomly chosen; and repeated AP-LDD using molsidomine in the opposite SFA. Post-procedural angiograms and lumenal diameter measurements were obtained as described above. After surgical closure of puncture site and wound, the pig was transferred to the postoperative suite for recovery.
Haemodynamics and wall rheology in SFAs, echodoppler
From a local incision, SFA was carefully freed (without apparent disruption of blood supply to the adventitia) from the profunda femoralis branch down to the PopA-postTA arteries bifurcation. Haemodynamics and wall mechanics measurements 29, 34 were centred on AP-LDD site and consisted of intravascular measurements of pulsatile blood pressure with a 2F Mikro-Tip Catheter pressure transducer SPR-249 (Millar Instruments, Inc., Houston, TX, U.S.A.). Pulsatile flow measurements were carried out by using the T206 blood flow meter (Transonic Systems, Inc., Ithaca, NY, U.S.A.) and appropriate perivascular RB flowprobes. Pulsatile external diameter was assessed by using a facing pair of ultrasonic probes (10 MHz) inserted within a silicone clip-probe, and connected to 4-channels sonomicrometer (Triton Technology Inc., San Diego, CA, U.S.A.).
Systolic and diastolic blood flow velocities at the PTA site (as a frame fixed in depth and centred length in between ISA branch and PopA-PostTA bifurcation) were further non-invasively investigated by Colour in the low range), CDE signal intensity was proved to be observer independent and influenced by fluid flow velocity, only. 35, 36 At the same depth and instrument probe) displaying the varying pulsatile flow velocities (see Fig. 3 ). From the video recordings, Adobe Premi-settings (as is the case in the study), the CDE signal was found to be proportional to the returning signal ere software (Adobe Systems Inc.) was used to digitise, extract and convert (into a 256 grey levels scale) the strength and to provide high-resolution cross-sectional display of the vessel which can be stored on video tape individual systolic and diastolic images along the original cardiac cycles triggered by the R-wave. The or numerised and subsequently subjected to computer analysis for extracting flow velocities from the scale SAMBA 2005 automatic scanning image analyser (TITN-Alcatel, Grenoble, France) 6,7,27,30 enables drawing given by the instrument. 35, 36 With standardised application, CDE was recorded in SFAs under constant a mid-vessel line along the entire segment to maintain identical length in systolic and diastolic images. The amplifying magnitude for 15 cardiac cycles with an HDI 5000 ATL echodoppler instrument (7.5 MHz optical density (OD) profiles were recorded pixel by pixel along the line and further converted to blood elastic fibres, or processed for immunohistological PCNA labelling. 28, 32 Morphometric analysis was pervelocities according to the instrument-dependent colformed under ×15-400 magnification light microour map, treated accordingly. Finally the blood velocity scopy, using an automatic videoanalyser, SAMBA 2005 values in individual cycles were averaged in the sys-(TITN-Alcatel, Grenoble, France). 6,7,27,30 Densitometry tolic and diastolic phases for both placebo or molanalysis of PCNA staining was computerised as the sidomine-treated legs; and profiles of velocities in the number of labelled nuclei per unit surface. In the averaged cycles were established using density count lesional sites, morphometric analysis of the arterial technique in Systat 9.0 statistical software (SPSS Inc., section geometry consisted of (i) delineating on the Chicago, IL, U.S.A.).
computer screen, the boundaries of the lumen, intimamedia and media-adventitia junctions, (ii) centring 24 radial pairs of 2 orthogonal diameters on the arterial Morphometry and immunocytochemistry section, and (iii) measurement of 96 triplets of radial lumen, intima and media thickness. In each sample at Immediately after haemodynamics measurements, the the lesional site, the distribution of the morphometric animals were euthanised (midazolam 15 mg and chlordata were further submitted to density count analysis, promazine 25 mg in KCl 15% (p/v), 20 ml, i.v. bolus) and further averaged to yield the final density count and serial pathologic slides, orthogonally sectioned profile per leg and per animal. (6 m) were obtained after in situ fixation with 10% formalin under a constant 120 mmHg perfusing pres-Statistical analysis sure. 28, 32 Deparaffined slides were stained with Masson's trichrome for general observation or with the Data treatment and statistical analyses were performed by using Systat 9.0 software (SPSS Inc., Chicago, IL, Lillie and Fullmer's orceine for specific staining of U.S.A.). Results are expressed as mean±standard de-mm 2 , at the AP-LDD with placebo and molsidomine, respectively (p<0.001), which indicate that, 24 h after viation (SD). In constructing and analysing the blood velocities and vessel dimensions, multicates in each angioplasty, molsidomine delivery maintained cell proliferation state to baseline level of 9±2 stained leg and in each subject were averaged to yield an individual value or profile subjected to dot density nuclei/mm 2 . 27 Finally, local delivery of molsidomine as compared to placebo delivery at the time of an-count analysis along the horizontal data scale at the location of data values. Statistical analysis of the meas-gioplasty induced parallel magnification of both systolic (374±54 vs 135±34 ml/min) and diastolic ures for molsidomine-treated arterial sites vs controls was performed by using the Kruskal-Wallis test (i.e. (176±51 vs 78±13 ml/min) flows with increased mean blood flow (374±54 vs 135±35 ml/min) the non-parametric analogue of a one-way analysis of variance), which reduced to the Mann-Whitney test (p<0.05), due to increased compliance in the treated sites (90±10 vs 27±5 ml/mmHg) (p<0.05), re-(i.e. the non-parametric analogue of the two-sample ttest) when there are only two groups.
spectively.
Angioplasty with LDD, mid-term results at 5 months Results
As they were in pre-procedure angiograms, luminal Atherosclerosis model diameter narrowing was observed in some of the placebo-treated sites (Fig. 2) . The early vasodilatory The animals remained healthy throughout the prochanges in the haemodynamics and wall mechanics gram period. At 6 months, the atherogenic diet ininduced by molsidomine delivery during angioplasty creased cholesterol-related serum parameters in the persisted at 5 months, as compared to the placebo swines ( Fig. 1 ) without significant additional changes sites: both maximum (270±98 vs 171±82 ml/min) in the serum biochemistry. 6,27 the type IIa hyand minimum (85±57 vs 57±14 ml/min) flows had percholesterolemia-induced atherosclerotic lesions parallel magnification due to increased compliance were detectable under gross pathologic examination (66±9 vs 11±4 ml/mmHg) and lowered entry imof the SFA proximal to the angioplasty site at 24 h pedance (0.11±0.05 vs 0.45±0.10 mmHg/ml min −1 ) (Fig. 1) . These lesions had the common pathological (p<0.05), which also indicate the worsening situation appearance relevant to the reported assessment of at the placebo-treated site. human lesions. 6,7,27 Upon examination of the pre-In dot histograms (Fig. 3) showing the density (with angioplasty arteriograms, angiographic reduction in a unique symbol as the relative concentration of data luminal diameter was observed ( Fig. 2a ) in some points in intervals) of every velocity across the range instances but not generally influencing the average of the distribution, non-invasive haemodynamic indiameter.
vestigations in the SFA at 5 months demonstrated that, in SFAs following angioplasty with placebo delivery, blood flow elicited a 3 peak-shaped distribution of velocities in both the systolic and diastolic situations Angioplasty with LDD due to the emergence of a lowest velocity group. By definition, low, middle and high velocities peaked at The BSC-CB device was placed and inflated in the SFA in all cases ( Fig. 2a ). No acute complication occurred 7.5, 20 and 35 cm s −1 and 8, 15 and 22 cm s −1 in the systolic and diastolic flows, respectively. The results during intraSFA insertion, deployment, liquid solution delivery or retrieval of the balloon along the guidewire. show that both diastolic and systolic flows were increased at the molsidomine delivery sites, due to a The average SFA lumen diameter at the dilatation site was similar in both SFAs before angioplasty: shift of the lowest velocities to the higher range of the spectrum. Specifically, the density counts in the systolic (5.5±0.2 mm; n=28 vessels). At 24 h (n=4), the SFA luminal diameter was 5.7±0.2 mm (n=4) and peaks of velocity were 9.4±1.1 vs 0.7±0.1 * , 40.2±3.9 vs 28.8±3.1, and 48.9±5.4 vs 103.2±12.1 counts for 5.9±0.3 mm (n=4) at the AP-LDD with placebo and molsidomine, respectively, which shows that equi-the placebo vs molsidomine-treated angioplasty sites ( * : p<0.01), respectively; and similarly the density valent angioplasty was performed at both sites. In the arterial wall at 24 h, the number of PCNA-positive counts for the diastolic flows, the density counts were 19.1±3.0 vs 8.7±1.6 * , 93.8±9.6 vs 99.2±7.3, and nuclei, i.e. the proliferating nuclei, was found to be 33±14 stained nuclei/mm 2 and 12±3 stained nuclei/ 37.5±5.2 vs 139.4±11.2 counts for the placebo vs 1.10±0.12 mm in the molsidomine-treated site, whereas the placebo-treated site had a dramatically enlarged peak centred at 0.85±0.24 mm (p<0.001). Finally, the mean lumenal radius in the placebo-treated and molsidomine-treated PTA sites were 2.6±0.34 and 3.4±0.31 mm, respectively (p<0.05). The results indicate that PTA-LDD-M prevented the increases in both the intima thickness and intima-media ratio, as well as the media thinning. As a consequence, the lumenal radius was lowered by 24% in the placebotreated arm as compared to the treated arm (p<0.05).
Discussion
The main result of the present study is that local delivery of the aqueous perfusate of NO-donor parent compound molsidomine at the time of angioplasty livery of molsidomine in the porcine SFA minimised occurrence of (i) a low-velocity pattern in blood flow, known to favour development of arterial lesions, 37,38 molsidomine-treated angioplasty sites ( * : p<0.01), respectively. Therefrom, AP-LDD with molsidomine cre-and (ii) a focalised intimal thickening and converse media thinning with an increased intima/media ratio, ated a homogeneous blood flow distribution and the treatment did not increase the blood flow velocities thereby leading to a larger lumenal diameter in treated vessels. Finally, the safety of PTA procedure is sup-outside of the spectrum range in the placebo-treated SFAs.
ported by early angiographic results which did not show any significant arterial damages or differences Pathologic examinations of the PTA sites in the explanted SFA segments at 5 months revealed non-between LDD with placebo or molsidomine.
Haemodynamics and wall mechanics at endo-lipidic fibrosclerotic and cell proliferations and alterations of the elastic structures, histologic char-vascular intervention play a significant role in the location, development, progression of atherosclerosis, acteristics of restenotic processes with (Fig. 4) . Morphometric analysis of the lesions identified the early and late restenosis, as well as the propensity for subacute thrombosis. 37, 38 Consequently, in the SFA restenosis-associated intimal thickening and converse medial thinning; and increased intima-media ratio and it is established that return to normal ankle-brachial pressure index (ABPI >0.9 at 24 h) is a strong lowered lumenal diameter (Fig. 4) . Specifically, intimal thickness in the placebo-treated site was characterised indicator of a favourable long-term prognosis after angioplasty. 1 By investigating the vessel compliance by the emergence of a density peak at 0.75±0.12 mm and an increased density peak at 0.48±0.14 mm which estimates how the elastic wall reacts in response to the haemodynamic forces, as well as (p<0.05 as compared with the molsidomine-treated site); whereas the molsidomine-treated sites had a how the vessel recoils to further propel blood flow along the vasculature, 39 we have shown that homogeneous peak (at 0.21 mm) in intimal thickness. Similarly, the intima-media ratio evidenced two dens-molsidomine delivery led to a persistent increase in the SFA vascular strain (i.e. changes in volume due ity peaks (centred at 0.28 (80%) and 0.60 (20%)) in the placebo-treated sites, whereas a single density peak at to wall circumferential elongation) in response to the stress (i.e. distending blood pressure wave). This 0.16 was characteristic of the intima/media ratio in the molsidomine-treated site. The medial thickness in turn resulted in decreased entry impedance and increased blood flow with constant pulse flow. The peak was uniformly shaped and centred at latter is further demonstrated by colour Doppler Future directions/next steps energy investigations revealing that PTA-LDD-M prevented emergence of restenosis-associated low We report here the mid-term therapeutic efficacy of local molsidomine delivery at the time of angioplasty blood velocities. As mechanical forces play an important role in the modification of the vascular under the experimental conditions of pre-existing atherosclerotic lesions in the porcine SFA. The ex-structure, it is presently accepted that the vessel remodels its geometry, structure and composition in perimental protocol was based upon technically challenging solutions for simultaneous local drug de-response to angioplasty in a way to produce a more homogeneous stress distribution from the inner wall livery and angioplasty derived to address the key determinants in SFA restenosis. The design of the to the outer wall. 40 It is also acknowledged that these remodelling targets may be reached at the channelled angioplasty balloon enables delivery of adequate quantities of drug to the vessel wall without expense of pathological changes in wall metabolism and mechanical properties. 41 The residual strains, either injuring the wall or compromising flow. The commercially available, aqueous i.v. perfusate allows which determine the stress distribution through the artery wall following geometrical changes, 40 are penetration, retention and convection of the 4 mg administered drug by using the increased hydraulic con-concentrated in the inner, intimal layers, which contain more elastin than the collagenous outer ductance of atherosclerosis. The optimisation of the NO-donor molecule, which is retained for several layers which contribute little to the residual strains. From these, the inner layers remodel themselves in days and continuously released, avoids the risk of cell toxicity due to a concentrated localised presence of response to stress concentration by developing more compressive residual strains than the outer layers. 41 NO within the vessel wall. Additionally, NO, as the active agent, possesses the "multi-purpose" phar-By preserving the integrity of the internal elastic laminae, molsidomine delivery obviously favours the macologic properties addressing the "multi-component" compensatory responses of the restenotic latter processes. On the other hand, changes in arterial compliance, detectable as early as at 24 h after development in the atherosclerotic SFA.
Finally, caution has to be taken in extrapolating the molsidomine delivery, may be due to a synergistic combination of adaptive structural changes and of present results because of the reported disparity laying between animal model data and clinical trial ex-relaxation in arterial smooth muscle tone. This would in turn alter the relative loading of collagen and perience. 16 The efficacy for the present protocol established for angioplasty with local molsidomine elastin fibres by transferring stress from the less extensive collagen fibres to elastin. 42 The net result delivery will be examined in a controlled clinical trial as the next step. of these structural adaptations is that intimal layers and endothelial cells are in a new dynamic equilibrium with their ambient fluid and solid mechanical environment. 43 The observation of beneficial, thera-References peutic effects for molsidomine delivery implies that cellular activation in the vessel wall at time of 
